---
title: "Palmitoyl Pentapeptide-4"
canonical_url: https://peptidelibrary.app/library/palmitoyl-pentapeptide-4
description: "Palmitoylated KTTKS matrikine (Matrixyl) used in anti-wrinkle cosmetics. Not an FDA drug. Not WADA-prohibited as a cosmetic peptide."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Palmitoyl Pentapeptide-4

Palmitoyl Pentapeptide-4 (also called Matrixyl or Pal-KTTKS) is a cosmetic matrikine in the Matrix / Angiogenic class. Palmitoyl pentapeptide-4 is the KTTKS sequence, a fragment of type I procollagen, with a palmitic acid chain attached to improve penetration through the stratum corneum.

Palmitoylated KTTKS matrikine (Matrixyl) used in anti-wrinkle cosmetics. Not an FDA drug. Not WADA-prohibited as a cosmetic peptide.

Also known as: Matrixyl, Pal-KTTKS.

Categories: Cosmetic, Experimental.

## Classification

- Type: Cosmetic matrikine
- Mechanism class: Matrix / Angiogenic
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Palmitoyl pentapeptide-4 is the KTTKS sequence, a fragment of type I procollagen, with a palmitic acid chain attached to improve penetration through the stratum corneum. It is a matrikine: fragments released during matrix breakdown act as feedback signals to fibroblasts that repair is needed. In fibroblast culture the peptide has been reported to increase synthesis of collagen types I and III and fibronectin. Controlled topical studies show modest reductions in wrinkle depth and roughness relative to vehicle. The effect is on matrix protein expression rather than on muscle contraction, so it is mechanistically unrelated to the SNARE-targeting cosmetic peptides.

Targets: Dermal fibroblasts, Collagen synthesis.

Origin: Synthetic palmitoylated pentapeptide.

## Properties

- Molecular formula: C39H75N7O10
- Molecular weight: ≈802.07 g/mol
- CAS number: 214047-00-4
- Half-life: Topical; systemic PK not established
- Studied routes: Topical

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 2
- Controlled human trials: 2
- Preclinical sources: 0
- Latest source: 2023

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Robinson LR et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005. 2005. Controlled human trial. Population: 93 Caucasian women aged 35–55. Well tolerated; significant reduction in wrinkles and fine lines vs placebo by image analysis and expert grading [Source](https://pubmed.ncbi.nlm.nih.gov/18492182/)
2. Aruan RR et al. Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. J Clin Aesthet Dermatol. 2023. 2023. Controlled human trial. Population: 21 Indonesian women aged 26–55 with crow's feet, split into three groups: acetylhexapeptide-3 cream, palmitoyl pentapeptide-4 cream and placebo. Improvements in several subjects with both creams; the authors reported better results with palmitoyl pentapeptide-4 than with acetylhexapeptide-3 or placebo and called it an initial study needing more subjects [Source](https://pubmed.ncbi.nlm.nih.gov/36909866/)

## Safety

Side effects: Mild irritation.

Risks: Cosmetic, not a drug.

Human safety basis: Limited human reports

Key limitations: No established human dosage.; Not approved by the FDA for any use..

## Regulatory status

Palmitoyl Pentapeptide-4 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Permitted
- Availability: OTC / Supplement

## Frequently asked questions

### What is Palmitoyl Pentapeptide-4?

Palmitoylated KTTKS matrikine (Matrixyl) used in anti-wrinkle cosmetics. Not an FDA drug. Not WADA-prohibited as a cosmetic peptide.

### How does Palmitoyl Pentapeptide-4 work?

Palmitoyl pentapeptide-4 is the KTTKS sequence, a fragment of type I procollagen, with a palmitic acid chain attached to improve penetration through the stratum corneum. It is a matrikine: fragments released during matrix breakdown act as feedback signals to fibroblasts that repair is needed.

### Is Palmitoyl Pentapeptide-4 FDA approved?

No. Palmitoyl Pentapeptide-4 is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Palmitoyl Pentapeptide-4?

Reported half-life for Palmitoyl Pentapeptide-4 is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Palmitoyl Pentapeptide-4 banned in sport?

Palmitoyl Pentapeptide-4 is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Palmitoyl Pentapeptide-4?

Compounds most often compared with Palmitoyl Pentapeptide-4 include Palmitoyl Tetrapeptide-7, Palmitoyl Tripeptide-5, Acetyl Hexapeptide-8 and Acetyl Octapeptide-3. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Mesenchymal stem cell therapy using Pal-KTTKS-enriched carboxylated cellulose improves burn wound in rat model — Arch Dermatol Res, 2024](https://pubmed.ncbi.nlm.nih.gov/38850353/)
- [Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet — J Clin Aesthet Dermatol, 2023](https://pubmed.ncbi.nlm.nih.gov/36909866/)
- [Matrixyl Patch vs Matrixyl Cream: A Comparative In Vivo Investigation of Matrixyl (MTI) Effect on Wound Healing — ACS Omega, 2022](https://pubmed.ncbi.nlm.nih.gov/35874243/)
- [Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression — Tissue Eng Regen Med, 2017](https://pubmed.ncbi.nlm.nih.gov/30603464/)
- [Thêta-Cream versus Bepanthol lotion in breast cancer patients under radiotherapy. A new prophylactic agent in skin care? — Strahlenther Onkol, 2004](https://pubmed.ncbi.nlm.nih.gov/15127162/)
